PCV Impact Assessment
Location
Sylhet District, Bangladesh
Background
This study in Sylhet district, Bangladesh, will evaluate the effectiveness of a 10-valent pneumococcal conjugate vaccine (PCV) against invasive disease.
Study Objectives
- Measure the rate of invasive (culture confirmed) pneumococcal disease (IPD) in the population before introduction of the PCV vaccine
- Measure the impact on clinical pneumonia, IPD, x-ray and ultrasound-confirmed pneumonia
- Measure the impact of PCV on nasopharyngeal carriage with Streptococcus Pneumoniae
- The study uses incidence trend and case-control study designs
Key Facts
- Pneumococcus is one of the most common causes of severe pneumonia, the leading infectious cause of death in children under-five
- WHO recommends that pneumococcal conjugate vaccines be included in the routine infant immunization program of all countries, and that each country conduct an impact assessment
- 10-valent conjugate vaccine (PCV10) and 13-valent conjugate vaccine (PCV13), available since 2009 and 2010, respectively, are replacing the earlier 7-valent conjugate vaccine (PCV7)
- Bangladesh introduced PCV10 in March 2015 and we are continuing to study the impact of this vaccine in this population of children
Principal Investigator
Abdullah H. Baqui, JHSPH
Local Principal Investigator
Abdul Quaiyum, ICDDR,B
Funding
- Bill & Melinda Gates Foundation
- GlaxoSmithKline